03/30/08 THU 12:48 FAX 610 270 4440

GLAXOSMITHKLINE

Ø1002

Docket No.: PU60365

## **DECLARATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as state I below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## "STABILIZED TOPOTECAN LIPOSOMAL COMPOSITION AND METHODS"

STABILIZED TOPOTECAN EN OSOMAL COM OSTRON AND METHODS					
the spo [ ] [X]	is attached her	25 June 2004	as Serial No. PCT/L	J <b>S2004/020592</b> plicable).	
		ive reviewed and unde d by any amendment		the above identified specification	on, including
		ty to disclose informately to disclose informately to the disclose informately the disclose informatel	tion which is material	to the patentability as defined in	Title 37,
I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.					
Prior I Numbe	Foreign Applica er	tion(s) Country	Filing Date	Priority Claimed	
I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.  Application Number Filing Date 60/483410 27 June 2003 60/530163 17 December 2003					
Section the sure Internal 112, I Code	on 365(c) of any bject matter of e ational application acknowledge the of Federal Regu	PCT International ap- each of the claims of the ion in the manner pro- ne duty to disclose info	plication designating this application is not ovided by the first paragormation which is manywhich became availab	ction 120 of any United States at the United States, listed below a disclosed in the prior United States graph of Title 35, United States terial to patentability as defined the between the filing date of the is application.	nd, insofar as tes or PCT Code, Section in Title 37,
Serial	No.	Filing Date	Status		

-2-

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor:

Residence:

1250 South Collegeville Road, Collegeville, FA 19426 PA

Citizenship:

United States

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW22 20

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Francis Ignatious

Inventor's Signature

Residence:

709 Swedeland Road, King of Prussia, PA 19406

Citizenship:

-India

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939